Although GlaxoSmithKline plc (GSK) is up over 5.4% in the past four weeks, investors may be concerned. After all, GSK is now in overbought territory, at least when looking at its RSI value of 70.2. If that wasn’t enough, investors should also note that GlaxoSmithKline possesses a Zacks Rank #5 (Strong Sell), so if analyst perception is any guide, we could witness a slump in GSK shares before too long.
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment